Podcast 23 Feb 2024
Precision neuromedicine: A new dawn for neurological disorders
This week on our podcast, explore how precision neuromedicine is reshaping neurological care with Rapport Therapeutics.
Clinical trial
- Latest Posts
In Depth 21 Feb 2024
Cytokine release syndrome: how pharma is tackling a 21st century disease
Explore the frontier of biotech’s battle against cytokine release syndrome (CRS), from historical setbacks to cutting-edge solutions.
In Depth 15 Feb 2024
Turning the tide: recent advancements in childhood cancer research
As we observe International Childhood Cancer Day today, let us take a look at some of the recent advancements in childhood cancer research.
In Depth 12 Feb 2024
RNA editing set to take off: could DNA’s short-lived cousin overcome the limitations of CRISPR gene editing?
Find out all about about RNA editing, as two candidates have just managed to reach the clinic for the first time.
In Depth 31 Jan 2024
New epilepsy drugs: what is in the pipeline?
Find out about the new epilepsy drugs currently in the pipeline, as resistance to current AEDs underscores the need for new treatments.
In Depth 26 Jan 2024
Long COVID: are we on the verge of a breakthrough?
Studies and recent developments in long COVID research could pave the way for more diagnostic and therapeutic opportunities.
ADVERTISEMENT
ADVERTISEMENT
In Depth 4 Jan 2024
Can GLP-1 agonists, the miraculous obesity drugs, treat cardiovascular diseases?
Discover how GLP-1 agonists, known for treating diabetes and obesity, are now being studied for their potential in tackling heart diseases.
Best in Biotech 21 Dec 2023
Five companies racing to bring their NASH treatments toward the finish line
NASH is a severe form of non-alcoholic fatty liver disease (NAFLD), where fat builds up on the liver, potentially leading to liver damage or cirrhosis. With no U.S. Food and Drug Administration (FDA)-approved treatments for the disease, many NASH companies are currently attempting to bring their candidates toward approval. In this article, we take a […]
Opinion 18 Dec 2023
What to expect from biotech clinical trials in the coming year
As cancer research has seen an increase in funding lately, here are some of the key clinical trends that you can expect in 2024.
Weekly Roundup 15 Dec 2023
Pharvaris’ $300 million public offering; Genentech’s breast cancer trial success; new neuromuscular disease target discovered
What’s been going on in the world of biotech of late? Find out with Labiotech’s weekly roundup of the latest biotech news.
Weekly Roundup 8 Dec 2023
Xenon’s $345 million public offering; EyePoint Pharmaceuticals’ trial success; gene therapy found to reduce liver cancer
What’s been going on in the world of biotech of late? Find out with Labiotech’s weekly roundup of the latest biotech news.
News and Trends 1 Dec 2023
Arvinas raises $350 million; Exonate’s trial reaps success; new cancer drugs discovered
Here is Labiotech’s weekly roundup of the latest biotech news. Stay in the loop by subscribing to our newsletter for direct updates to your inbox. The latest biotech news in fundraising In the news this week, biotech Arvinas raises $350 million PIPE American protein degradation company Arvinas has bagged $350 million in a private placement (PIPE). The […]
ADVERTISEMENT
